目的:了解达托霉素相关嗜酸粒细胞性肺炎（EP）的临床特点。方法:检索PubMed、Web of Science、Embase、SpringerLink、Wiley Online Library、ScienceDirect数据库（截至2020年5月31日），收集报道达托霉素相关EP的病例报告类文献，应用自行设计的Excel数据提取表记录患者基本情况、达托霉素日剂量、EP发生时间、临床表现、辅助检查结果以及治疗和转归情况，就达托霉素相关EP的临床特点进行描述性统计分析。结果:共收集到相关病例报告类文献31篇，报道达托霉素相关EP患者43例。43例患者中男性36例（83.7%），女性7例（16.3%）；年龄28~89岁，≥60岁者34例（79.1%）；患有急慢性肾病、心血管疾病、糖尿病等基础疾病者37例（86.0%）；6例患者达托霉素日剂量超过药品说明书推荐剂量；应用达托霉素至发生EP的时间为4 h~8周，≤4周者37例（86.0%）。达托霉素相关EP的主要临床表现为发热（97.7%，42/43）、呼吸困难伴低氧血症（81.4%，35/43）和咳嗽（51.2%，22/43），因呼吸衰竭使用人工辅助通气者占30.2%（13/43）。43例患者的胸部影像学检查肺部均出现新的浸润性病灶。40例有外周血嗜酸粒细胞检查结果描述，39例（97.5%）存在外周血嗜酸粒细胞比例和/或计数升高；27例患者行支气管肺泡灌洗液检查，17例（63.0%）嗜酸粒细胞>25%。诊断EP后，43例患者均停用达托霉素并接受氧气吸入、机械通气辅助呼吸、退热、止咳等对症治疗，其中29例接受了糖皮质激素治疗。所有患者均在停用达托霉素后1~2周症状明显改善，1周~3个月胸部影像学检查恢复正常。结论:达托霉素相关EP多发生在用药4周内，老年及男性患者居多。尽管症状严重，但及时停药预后良好。“,”Objective:To explore the clinical characteristics of daptomycin-associated eosinophilic pneumonia (EP).Methods:The PubMed, Web of Science, Embase, SpringerLink, Wiley Online Library, ScienceDirect databases were searched (up to 31 May 2020). Case reports of daptomycin-associated EP were collected. The patient′s general situation, daily dose of daptomycin, time of EP occurrence, clinical manifestations, auxiliary examination, and the treatment and outcome were recorded into a self-designed Excel data sheet. The clinical characteristics of daptomycin-associated EP were analyzed by descriptive statistical method.Results:A total of 31 articles of case reports were collected, reporting on 43 patients with daptomycin-associated EP. The 43 patients includeed 36 males (83.7%) and 7 females (16.3%). the patients′ ages ranged from 28 to 89 years, of which 34 (79.1%) were ≥60 years old and 37 (86.0%) were suffering from diseases such as acute and chronic kidney disease, cardiovascular disease, diabetes, and etc. The daily dose of daptomycin in 6 patients exceeded the recommended dose in the drug instruction. The time from application of daptomycin to onset of EP was 4 hours to 8 weeks, and 37 (86.0%) of them were less than or equal to 4 weeks. The main clinical manifestations were fever (97.7%, 42/43) and dyspnea and hypoxemia (81.4%, 35/43), and cough (51.2%, 22/43), and artificial assisted ventilation was used in 30.2% (13/43) of patients due to respiratory failure. Forty-three patients had new invasive lesions in the lungs on chest imaging. Forty patients described peripheral blood eosinophil test results, and 39 (97.5%) had increased eosinophil proportion and/or count. Bronchoalveolar lavage fluid was performed in 27 patients and 17 (63.0%) had eosinophils >5%. After the diagnosis of EP, all 43 patients stopped using daptomycin. and received symptomatic treatments including oxygen inhalation, artificial assisted ventilation, defervescence, and cough suppression. Of them, 29 patients received glucocorticoid therapy. All the patients′ symptoms were improved significantly within 1-2 weeks and chest imaging returned to normal within 1-3 months.Conclusions:Daptomycin-associated EP mostly occurred within 4 weeks of treatment, mostly in elderly and male patients. Although the symptoms were severe, the prognosis was good when the drug was stopped in time.